Dateline – November 17, 2025 | San Jose, California Anixa Biosciences, Inc. announced that the WHO’s International Non-proprietary Names (INN) Expert Committee has approved “liraltagene autoleucel” as the non-proprietary name for its novel CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. This naming milestone marks a significant step toward global recognition and sets the stage for the therapy’s future commercialization under the brand moniker “lira-cel”.
Science Significance
Liraltagene autoleucel (lira-cel) is a first-in-class chimeric endocrine receptor-T cell (CER-T) therapy that specifically targets FSHR, a receptor expressed on tumor vasculature and certain ovarian cancer cells. By leveraging the natural ligand (FSH) as the targeting domain rather than an antibody fragment, it offers a differentiated approach in the CAR-T field. The assignment of an INN indicates the technology is at a stage where it can be referenced consistently in scientific discourse, regulatory filing and global clinical development, thereby advancing its scientific maturity and facilitating cross-border comparison.
Regulatory Significance
Approval of an INN by the WHO is an essential regulatory milestone signifying that the therapy is recognized globally as a distinct active substance. This facilitates standardized naming across clinical trials, label submissions, pharmacovigilance systems and medical communications. With the INN now secured, Anixa can proceed more efficiently with regulatory filings in multiple regions, strengthening its position for global commercialization and cross-border clinical development.
Advertisement
Business Significance
The assignment of a unique global name enhances the therapy’s commercial visibility and strengthens the company’s strategic positioning for future partnerships or licensing opportunities. It signals to investors that the program has reached a level of maturity consistent with advanced biopharmaceutical development. The INN approval also contributes to branding, intellectual-property clarity and long-term differentiation within an increasingly competitive immuno-oncology landscape.
Patients’ Significance
For patients with recurrent ovarian cancer—a condition with limited therapeutic options and high mortality—the recognition of liraltagene autoleucel marks a meaningful step forward. Progress toward clinical and commercial readiness increases hope for a treatment that may deliver improved targeting, reduced toxicity and more durable response potential. The development of this therapy underscores ongoing efforts to bring next-generation cell therapies to populations with high unmet medical needs.
Policy Significance
The WHO’s approval reflects broader global efforts to standardize nomenclature for advanced cell therapies, supporting safe prescribing and international pharmacovigilance. It aligns with global policy trends promoting innovation, consistency and traceability for cutting-edge biologics. As cell therapies expand, such frameworks guide national regulators, healthcare providers and reimbursement bodies in managing emerging technologies responsibly
The approval of the INN “liraltagene autoleucel” marks a pivotal advancement in Anixa Biosciences’ journey to develop a transformative CER-T therapy for ovarian cancer. This regulatory milestone strengthens scientific credibility, enhances global readiness and underscores the therapy’s potential impact on future cancer treatment. With momentum building, the company is moving closer to delivering a novel immunotherapy to patients in urgent need.
Source: Anixa Biosciences, Inc press release
